• BMS-345541 Hydrochloride: Redefining IKK Inhibition in Trans

  2026-05-14

  This thought-leadership article explores the mechanistic underpinnings and translational impact of BMS-345541 hydrochloride, a highly selective IKK inhibitor, for researchers advancing inflammation and T-ALL studies. By integrating evidence from recent anti-inflammatory stent research and benchmarking against the broader competitive landscape, it provides actionable guidance on experimental design and strategic application, culminating in a forward-looking perspective on NF-κB modulation.

• Oxaliplatin: Protocols & Troubleshooting in Cancer Chemother

  2026-05-14

  Oxaliplatin, a platinum-based chemotherapeutic agent, offers robust cytotoxicity for preclinical and translational cancer models. This guide delivers actionable workflows, experimental optimizations, and troubleshooting strategies to maximize the reliability of Oxaliplatin-based assays—empowering researchers in metastatic colorectal cancer therapy and beyond.

• Heparin Sodium as a Glycosaminoglycan Anticoagulant: New Mec

  2026-05-13

  Discover how Heparin sodium, a leading glycosaminoglycan anticoagulant, is reshaping advanced coagulation and thrombosis research through mechanistic insight and innovative assay applications. This article explores novel scientific findings and practical protocols rarely discussed elsewhere.

• Trichostatin A (TSA): Epigenetic Modulation in Cancer and Bo

  2026-05-13

  Trichostatin A (TSA) is a gold-standard HDAC inhibitor powering breakthroughs in cancer epigenetics and bone regeneration. This guide decodes how TSA enables robust experimental workflows, highlights troubleshooting insights, and translates new findings—including its role in implant osseointegration—into actionable lab strategies.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-12

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, more accurately reproducing the cellular heterogeneity and drug response variability of primary tumors. The approach enables detailed investigation of tumor–microenvironment interactions and supports personalized drug screening for improved therapeutic strategies.

• Ruthenium Red as a Ca2+ Transport Inhibitor in Mechanotransd

  2026-05-12

  Ruthenium Red uniquely empowers researchers to dissect cytoskeleton-dependent calcium signaling and mechanotransduction, offering robust inhibition of mitochondrial and sarcoplasmic reticulum Ca2+ transport. This article provides actionable workflow guidance, troubleshooting strategies, and a direct translation of recent breakthroughs in mechanical stress-induced autophagy for optimized calcium signaling research.

• Belinostat (PXD101): Reliable HDAC Inhibition for Cancer Ass

  2026-05-11

  This article offers scenario-driven insights for optimizing cell viability and proliferation assays using Belinostat (PXD101), SKU A4096. Emphasizing evidence-based protocols and practical troubleshooting, it guides researchers in achieving reproducible, quantitative results in epigenetic cancer therapy studies. Practical comparisons and workflow tips highlight the advantages of Belinostat (PXD101) for rigorous biomedical research.

• Microfluidic Peptide/mRNA Complexes Enable Efficient Pulmona

  2026-05-11

  This study introduces a microfluidic mixing approach to create robust peptide/mRNA complexes suitable for pulmonary delivery by nebulisation. The findings demonstrate preserved transfection efficiency post-nebulisation, suggesting significant potential for clinical applications in lung-targeted mRNA therapeutics.

• Heparin Sodium in Thrombosis Research: Protocols & Innovatio

  2026-05-10

  Heparin sodium is a benchmark glycosaminoglycan anticoagulant for modeling the blood coagulation pathway and optimizing anti-factor Xa activity assays. This article details practical workflows, highlights protocol advancements, and translates new nanovesicle biology into actionable strategies—enabling researchers to maximize reproducibility and innovation in thrombosis studies.

• Plant Exosome-Like Nanovesicles Restore Sertoli Cell Functio

  2026-05-09

  This study demonstrates that exosome-like nanovesicles derived from Cistanche deserticola (CDELNs) are taken up by Sertoli cells via heparan sulfate proteoglycans, delivering miR159b-3p to alleviate cyclophosphamide-induced cell cycle arrest. The findings open new avenues for cell-targeted therapies in testicular injury and highlight the interplay between nanovesicle uptake and glycosaminoglycan biology.

• Allosteric PDK4 Inhibitors: Advancing Metabolic Disease Rese

  2026-05-08

  This study introduces a new class of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, notably compound 8c, with high in vitro potency and promising efficacy in metabolic, allergic, and cancer models. The findings highlight the therapeutic potential of PDK4 modulation for metabolic disease intervention and provide a new scaffold for drug development.

• MDV3100 (Enzalutamide): Experimental Workflows in Prostate C

  2026-05-08

  Unlock the full potential of MDV3100 (Enzalutamide) with advanced, evidence-based workflows for dissecting androgen receptor signaling and overcoming resistance in prostate cancer research. This guide details stepwise protocols, key senescence insights, and troubleshooting strategies that maximize data quality—making it essential for any lab investigating castration-resistant prostate cancer.

• PEDV Rewires IMPDH-Dependent Nucleotide Synthesis for Replic

  2026-05-07

  This study uncovers how porcine epidemic diarrhea virus (PEDV) manipulates host IMPDH-dependent guanosine biosynthesis to promote its replication in cell models. By demonstrating that both genetic and pharmacological inhibition of IMPDH—specifically with Merimepodib (VX-497)—markedly suppresses PEDV replication, the research establishes IMPDH as a promising host-directed antiviral target for veterinary coronaviruses.

• Erastin (SKU B1524): Reliable Ferroptosis Inducer for Cancer

  2026-05-07

  Discover how Erastin (SKU B1524) addresses core laboratory challenges in ferroptosis research, from protocol optimization to data interpretation and vendor selection. This article delivers actionable, evidence-based guidance for scientists seeking reproducible and selective induction of iron-dependent, non-apoptotic cell death in RAS- and BRAF-mutant tumor models.

• Dabigatran (Pradaxa): Optimizing Thrombin Inhibition Workflo

  2026-05-06

  Dabigatran (Pradaxa) stands at the forefront of direct thrombin inhibition, enabling robust, reproducible results in coagulation assays and translational anticoagulation research. This article dissects experimental workflows, protocol optimizations, and troubleshooting strategies that leverage APExBIO’s Dabigatran for both mechanistic and applied studies.

16172 records 1/1079 page Next 12345 下5页 Last page